Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib

Nearly half of patients with advanced and metastatic melanomas harbor a BRAF mutation. Vemurafenib (VEM), a BRAF inhibitor, is used to treat such patients, however, responses to VEM are very short-lived due to intrinsic, adaptive and/or acquired resistance. In this context, we present the action of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nisiewicz, Monika K., Kowalczyk, Agata, Sobiepanek, Anna, Jagielska, Agata, Wagner, Barbara, Nowakowska, Julita, Gniadek, Marianna, Grudzinski, Ireneusz P., Kobiela, Tomasz, Nowicka, Anna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794875/
https://www.ncbi.nlm.nih.gov/pubmed/33406789
http://dx.doi.org/10.3390/ijms22010439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794875/
https://www.ncbi.nlm.nih.gov/pubmed/33406789
http://dx.doi.org/10.3390/ijms22010439

Ejemplares similares